贝达喹啉对耐多药、广泛耐药肺结核患者的临床疗效与安全性  

Clinical Efficacy and Safety of Bedaquiline in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Patients

作　　者：刘凤霞[1] 常婷婷 LIU Fengxia;CHANG Tingting(Department of Tuberculosis Internal Medicine,Shandong Public Health Clinical Center,Shandong University,Jinan 250013,China)

机构地区：[1]山东大学附属公共卫生临床中心结核内科,济南250013

出　　处：《中国医药指南》2024年第25期38-40,共3页Guide of China Medicine

摘　　要：目的分析贝达喹啉对耐多药、广泛耐药肺结核患者的临床疗效与安全性。方法选取2020年4月至2022年4月山东省公共卫生临床中心结核内科收治的耐多药结核病、准广泛耐药结核病及广泛耐药结核病患者100例为研究对象,均接受背景方案及贝达喹啉24周治疗,记录患者的治疗转归,评估疗效和安全性。结果共80例完成24周治疗,80例(100%)均痰菌阴转,50例(62.5%)病灶显著吸收,22例(27.5%)吸收。存在肺部空洞的56例患者中,39例(69.6%)空洞闭合,12例空洞缩小。30例(30.0%)患者出现QTcF延长,3例(3.0%)出现心悸反应。结论贝达喹啉治疗耐多药、广泛耐药肺结核患者取得了积极的疗效,治疗相关的心脏不良事件和QTcF的延长仍然需要谨慎监测。Objective To analyse the clinical efficacy and safety of bedaquiline in multidrug-resistant and extensively drug-resistant tuberculosis patients.Methods A total of 100 patients with multidrug-resistant tuberculosis,quasi-extensively drug-resistant tuberculosis and extensively drugresistant tuberculosis admitted to the Department of Tuberculosis Internal Medicine,Public Health Clinical Centre of Shandong Province from April 2020 to April 2022 were selected as the study subjects,and all of them were treated with background regimen and 24-week treatment with bedaquiline,and the regression of the patients'treatment was recorded,and the efficacy and safety were assessed.Results A total of 80 cases completed 24 weeks of treatment,all 80(100%)were sputum negative,50(62.5%)had significant lesion resorption and 22(27.5%)had resorption.Of the 56 patients with lung cavities,39(69.6%)had cavity closure and 12 had cavity shrinkage.30(30.0%)patients had QTcF prolongation and 3(3.0%)had palpitation response.Conclusions Bedaquiline has achieved positive efficacy in the treatment of patients with multidrug-resistant and extensively drug-resistant tuberculosis,and treatment-related adverse cardiac events and QTcF prolongation still need to be carefully monitored.

关 键 词：贝达喹啉 耐多药 广泛耐药 肺结核 临床疗效 安全性 

分 类 号：R521[医药卫生—内科学] R978.3[医药卫生—临床医学]